Xin Lu (Ludwig Institute for Cancer Research, United Kingdom) “p53, a Key Regulator of Genomic Stability in Cancer” Discovery of p53: 1979 about the same time “tumor antigen” by Lloyd and Old, PNAS. Binding partner of large T antigen of SV40 (A Larid and David Lane) p53 mutation in 30–40% BL, why only 9 % in […]
Andrew Futreal (University of Texas MD Anderson Cancer Center, USA) “Cancer Genomics and Evolution” tumors heterogeneous from one patient to another intratumor heterogeneity—a state where subclonal subpopulations within the same tumor accumulate different kinds of mutations over time (65% heterogeneity in RCC) 1 mutation/wk, 40 mutations / year APOLLO platform https://goo.gl/uRmjHX Moon shot platform 40% subclonal
GRC NPC – Futreal, Andrew Read More »
Allan Hildesheim (National Cancer Institute, NIH, USA) “Use of Viral and Genetic Markers for Risk Stratification for Development of Screening Programs for the Early Detection of NPC” 1987 Use of viral and genetic markers for NPC risk stratification. 16% cancers are caused by infectious agents (Lancet Oncol 2012, de Martel) EBV vaccination: EBV gp350 (Coghill et
GRC NPC – Hildesheim, Allan Read More »
Harald zur Hausen (German Cancer Research Center, Germany) “Discovery and Early Studies of EBV in Burkitt’s Lymphoma and NPC” EBV provides a step in the malignization of pre-malignant NPC lesion (methylation of p16) Endemic multiple sclerosis TGFb is an inducing agent for EBV lytic replication Vit D deficiency -> TGFb increase -> EBV reactivation EBV enhances
GRC NPC – zur Hausen Read More »
Wed Poster #5 Dr. Timothy Wai Ho Shuen 孫傳豪 Singapore TESSA therapeutics (http://goo.gl/zdbYpA) NPC stage IVb patients → 抽300-400 ml blood → 一部分加B95-8 養成LCL → 養成的LCL與病人自己PBL aliquot co-culture → mapping 出effective CTL → expand → 打回去病人身上 (response rate還蠻不錯的! 整個時程約1-2個月) Wed Poster #9 University of Malaya Velapasamy, Sharmila … LF Yap SB-431542 10 uM, a TGFBRI
GRC NPC – Unclassified Read More »